SynAgentics Introduces Fundark and Stateam LLC as Partners

SynAgentics Biosciences is pleased to introduce Fundark Corp. and Stateam LLC as partners in the first edition of SynAgentics News.

We’re building the SynAgentics Research Hub to help scientists gather evidence, assess early candidates, and decide which findings warrant a closer look. That work involves two practical questions. How can AI tools fit into the way research teams already work? And how can scientists trace the evidence and assumptions behind an output? Fundark and Stateam bring experience that speaks to both.

Fundark Corp.

Fundark is an enterprise technology company whose AI work includes agents for internal knowledge management and workflow automation. The company describes a delivery process that starts with assessing how an organization works, then moves through implementation and ongoing support. Its offerings also include local deployment of open-source models and model environments tailored to specific needs.

That perspective matters as we develop the Research Hub for use by research teams. A scientist might begin with a literature question in SynLit, inspect the underlying sources, and pass the findings to a colleague for review. How easily the team can carry out those steps matters as much as the quality of the initial answer. Fundark’s focus on deploying AI within existing workflows is relevant to how we think about that experience. Learn more about Fundark

Stateam LLC

Stateam LLC is a Princeton, New Jersey–based, SBA-certified 8(a) small business that works in clinical research, biostatistics, regulatory affairs, and health analytics. Its services include study and protocol design, statistical analysis planning, and reporting. Stateam EDC combines electronic data capture with study implementation and data management. Parity, another Stateam product, checks whether modernized statistical programs reproduce the outputs of the original programs.

Stateam’s experience is relevant to how we present computational findings for scientific review. In SynRen, a predicted kidney-toxicity risk is a starting point for prioritizing follow-up. In SynADC, researchers need to see which candidate design, sources, and computational results informed an assessment. In both cases, the evidence behind an output helps researchers judge how much weight to give it and what to test next.

We thank both teams for their partnership. As SynAgentics develops the Research Hub and prepares for pilots, we’ll use SynAgentics News to share product walkthroughs, research examples, and updates from our team.

Learn more about Stateam LLC · Explore the SynAgentics Platform · Contact SynAgentics